Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma

M Mark R. Dowling (1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia) E Edward R. Scheffer Cliff (1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia) A Anthony Jeffrey (4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia) C Catelyn Cashion (6Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, Australia) S Stephen Boyle (7Cancer Care Services, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Brisbane, Australia) J Jian Li T Thomas Buss (12Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia) R Ross MacDonald (7Cancer Care Services, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Brisbane, Australia) A Anastasia Edelkina (3Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia) H Hamish W. Scott (1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia) N Nicole L. O’Leary (1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia) M Michelle W. Keir (4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia) S Safia Belbachir (12Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia) D David A. Westerman (1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia) C Constantine S. Tam (40Department of Haematology, Alfred Hospital and Monash University, Melbourne, VIC, Australia) P P. Joy Ho (4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia) S Simon J. Harrison A Allison Barraclough (12Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia) S Shafqat Inam (10Malignant Haematology, Transplantation and Cellular Therapy Service, Alfred Hospital, Melbourne, Australia) E Emily Blyth (5Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia) A Andrea S. Henden (7Cancer Care Services, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Brisbane, Australia) V Vinay Vanguru (4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia) M Michael J. Dickinson (1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia)

Abstract

Abstract In this retrospective analysis of 584 patients who received chimeric antigen receptor T-cell therapy for large B-cell lymphoma at 6 Australian centers, no association was found between time of infusion and outcome, accounting for confounders, suggesting minimal clinical impact of chronobiology in this setting.

Article Details

Journal Blood
Volume / Issue Vol. 147, Issue 19
Published May 07, 2026
Pages 2272-2277
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (23)

M

Mark R. Dowling

1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia

E

Edward R. Scheffer Cliff

1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia

A

Anthony Jeffrey

4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia

C

Catelyn Cashion

6Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, Australia

S

Stephen Boyle

7Cancer Care Services, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Brisbane, Australia

J

Jian Li

T

Thomas Buss

12Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia

R

Ross MacDonald

7Cancer Care Services, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Brisbane, Australia

A

Anastasia Edelkina

3Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia

H

Hamish W. Scott

1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia

N

Nicole L. O’Leary

1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia

M

Michelle W. Keir

4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia

S

Safia Belbachir

12Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia

D

David A. Westerman

1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia

C

Constantine S. Tam

40Department of Haematology, Alfred Hospital and Monash University, Melbourne, VIC, Australia

P

P. Joy Ho

4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia

S

Simon J. Harrison

A

Allison Barraclough

12Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia

S

Shafqat Inam

10Malignant Haematology, Transplantation and Cellular Therapy Service, Alfred Hospital, Melbourne, Australia

E

Emily Blyth

5Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia

A

Andrea S. Henden

7Cancer Care Services, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Brisbane, Australia

V

Vinay Vanguru

4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia

M

Michael J. Dickinson

1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia